Новые перспективы в лечении устойчивой к лечению гипертонии
DOI:
https://doi.org/10.52692/1857-0011.2024.1-78.14Ключевые слова:
ртериальная гипертензия, резистентная к лечению, апроцицентан, фирибаст, баксдростат, десимпатизация почечных артерийАннотация
Pезистентная гипертония представляет собой значительное бремя для всех систем здравоохранения во всем мире из-за ее связи с чрезвычайно высоким сердечно-сосудистым риском и остается терапевтической трудностью, обусловленной сложными физиологическими путями, которые недостаточно решаются традиционной терапией. В дополнении к фармакологической терапии, исследования показывают многообещающие доказательства десимпатизация почечных артерий при лечении резистентной aртериальной гипертензии. Более использование одобренных в настоящее время методов лечения и интеграция новых методов лечения является арсенал антигипертензивных препаратов.
Библиографические ссылки
Carey R.M., Calhoun D.A., Bakris G.L. et al.. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension 2018;72:e53–90.
Kearney P.M., Whelton M., Reynolds K., Muntner .P, Whelton P.K. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23.
Noubiap J.J., Nansseu J.R., Nyaga U.F.et al.. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart 2019;105:98–105.10.1136/heartjnl-2018-313599
Kallioinen Noa, Hill A., Mark S., Helen E. Sources of inaccuracy in the measurement of adult patients’ resting blood pressure in clinical settings: a systematic review. J Hypertens. 2017 Mar; 35(3): 421–441.
Lee E.K.P., Poon P., et al.. Global burden, regional differences, trends, and health consequences of medication nonadherence for hypertension during 2010 to 2020: a meta-analysis involving 27 million patients. J Am Heart Assoc 2022;11:26582.10.1161/JAHA.122.026582
Bourque G.; Ilin J.V.; Ruzicka M.; Hundemer G.L. et al. Non-Adherence is Common in Patients with Apparent Resistant Hypertension: A Systematic Review and Meta-Analysis. Am. J. Hypertens.2023.
Champaneria M.K., Patel R.S., Oroszi T.L. When blood pressure refuses to budge: exploring the complexity of resistant hypertension. Front Cardiovasc Med 2023;10:1211199. 10.3389/fcvm.2023.1211199
Schiffrin E.L. Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens. 2001;14(6 Pt 2):83S- S89. https://doi.org/10.1016/s0895-7061(01)02074-x.
Correale M., Ferraretti A., Monaco I., Grazioli D. et all. Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand? Vasc Health Risk Manag. 2018;14:253–64. https://doi.org/10.2147/VHRM.S133921.
Sidharta P.N., Treiber A., Dingemanse J. Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan. Clin Pharmacokinet. 2015;54(5):457–71.
Angeli F., Verdecchia P., Reboldi G. Aprocitentan, a dual endothelin receptor antagonist under development for the treatment of resistant hypertension. Cardiology and therapy. 2021;10(2):397–406.
Oparil S., Acelajado M.C., Bakris G.L.,et al. Hypertension Nat Rev Dis Primers. 2018;4:18014. https://doi.org/10.1038/nrdp.2018.14.
Carey R.M., Calhoun D.A., Bakris G.L., Brook R.D., et al. American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Resistant hypertension: Detection, evaluation, and management: A scientific statement from the American Heart Association. Hypertension. 2018;
Aronow W.S. Approaches for the management of resistant hypertension in 2020. Curr Hypertens Rep. 2020;22:3.
Wright J.W., Mizutani S., Harding J.W. Focus on brain angiotensin III and aminopeptidase A in the control of hypertension. Int J Hypertens 2012;2012:1–12. 10.1155/2012/124758
Quantum Genomics—Firibastat Phase III to start by end of the year - Edison Group. https://www.edisongroup.com/research/firibastat-phase-iii-to-start-by-end-of-the-year/25253/ (6 June 2023, date last accessed). [Google Scholar] [Ref list]
Firibastat fails to improve BP in resistant hypertension: FRESH. https://www.healio.com/news/cardiology/20221111/firibastat-fails-to-improve-bp- in-resistant-hypertension-fresh (21 July 2023, date last accessed). [Google Scholar] [Ref list]
Schlaich M.P., Bellet M., Weber M.A.et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet North Am Ed 2022;400:1927–37. 10.1016/S0140-6736(22)02034-7
Freeman M.W., Halvorsen Y-D, Marshall Wet. al.. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med 2023;388:395–405.
Longland C. J., & Gibb, W. E. (1954). Sympathectomy in the treatment of benign and malignant hypertension; a review of 76 patients. The British Journal of Surgery, 41(168), 382–392.)
Esler M., Jennings G., Korner P., et al (1984). Measurement of total and organ-specific norepinephrine kinetics in humans. The American Journal of Physiology, 247(1 Pt 1), E21–E28.).
Johns E. J., Kopp U. C., DiBona G. F. (2011). Neural control of renal function. Comprehensive Physiology, 1(2), 731–767.)
Lauder L., Azizi M., Kirtane A.J., Böhm M., Mahfoud F. (2020) Device-based therapies for arterial hypertension. Nat Rev Cardiol 17:614–628.).
Mahfoud F., Kandzari D. E., Kario K., Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): A randomised, sham-controlled trial. Lancet, 399(10333), 1401–1410. https://doi.org/10.1016/S0140-6736(22)00455-X(2022).
Azizi M., Daemen J., Lobo M. D., Mahfoud. 12-month results from the unblinded phase of the RADIANCE- HTN SOLO trial of ultrasound renal denervation. JACC. Cardiovascular Interventions, 13(24), 2922– 2933. https://doi.org/10.1016/j.jcin.2020.09.054
Mahfoud F., Böhm M., Schmieder R., Narkiewicz K. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. European Heart Journal, 40(42), 3474–3482.(2019).
Hussam Al Ghorani, Saarraaken Kulenthiran, Lucas Lauder. Ultra-long-term efficacy and safety of catheter- based renal denervation in resistant hypertension: 10-year follow-up outcomes. Clin Res Cardiol (2024). https://doi.org/10.1007/s00392-024-02417-2
Kordalis A., Tsiachris D., Pietri P., et al. Regression of organ damage following renal denervation in resistant hypertension: A meta-analysis. Journal of Hypertension, 36(8), 1614–1621. (2018).
Schmieder R. E., Mahfoud F., Mancia G., Narkiewicz K., Ruilope L., et al. Clinical event reductions in high- risk patients after renal denervation projected from the global SYMPLICITY registry. European Heart Journal - Quality of Care and Clinical Outcomes, 9, 575–582. (2023).
Bhatt D. Presented at the American College of Cardiology Meeting 4 March 2023. HALO trial. In: acc.org/Latest-in-Cardiology/Clinical-Trials/2023/03/01
Epstein M., Marchena E.. Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the “end of the road” for renal denervation? J Am Soc Hypertens 2015.
Böhm M., Kario K., Kandzari D.E., Mahfoud F., et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet (2020)
Kandzari D.E., Böhm M., Mahfoud F., Townsend R.R., et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet (2018)
Azizi M., Schmieder R.E., Mahfoud F., et al Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet (2018).
Azizi M., Schmieder R.E., Mahfoud F., Weber MA, et al. Six-month results of treatment-blinded medication titration for hypertension control after randomization to endovascular ultrasound renal denervation or a sham procedure in the RADIANCE-HTN SOLO trial. (2019).
Azizi M., Sanghvi K., Saxena M., et al. Ultrasound renal denervation for hypertension resistant to a triple medica tion pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, shamcontrolled trial. Lancet (2021)
Syed M., Osman M., Alhamoud H., et al. The state of renal sympathetic denervation for the management of patients with hypertension: a systematic review and meta-analysis. (2021)
Ahmad Y., Kane C., Arnold A.D., et al. Randomized blinded placebo-controlled trials of renal sympathetic denervation for hypertension: a meta-analysis. Cardiovasc Revasc Med 34:112–118. (2022)
Mahfoud F., Mancia G., Schmieder R.E,. et al. Cardiovascular risk reduction after renal denervation according to time in therapeutic systolic blood pressure range. J Am Coll Cardiol 80(20):1871–1880. (2022).
Загрузки
Опубликован
Лицензия
Copyright (c) 2024 Вестник Академии Наук Молдовы. Медицина
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
